P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH

Bibliographic Details
Main Authors:	M. Jentzsch, L. Herrmann, L. Bischof, D. Backhaus, D. Brauer, G.-N. Franke, V. Vucinic, U. Platzbecker, S. Schwind
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000848116.66077.5d

Similar Items

P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
by: M. Jentzsch, et al.
Published: (2022-06-01)

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
by: Madlen Jentzsch, et al.
Published: (2022-12-01)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
by: Jule Ussmann, et al.
Published: (2023-08-01)

P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
by: L. Bischof, et al.
Published: (2022-06-01)

Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
by: Sebastian Schwind, et al.
Published: (2024-03-01)

P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
by: Lara Bischof, et al.
Published: (2023-08-01)

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
by: Dominic Brauer, et al.
Published: (2021-03-01)

P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
by: Georg-Nikolaus Franke, et al.
Published: (2023-08-01)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
by: Madlen Jentzsch, et al.
Published: (2023-08-01)

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS
by: J. Ussmann, et al.
Published: (2022-06-01)

High expression of the stem cell marker <i>GPR56</i> at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population
by: Madlen Jentzsch, et al.
Published: (2020-01-01)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
by: Madlen Jentzsch, et al.
Published: (2020-02-01)

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia
by: Madlen Jentzsch, et al.
Published: (2019-02-01)

Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis
by: Giuseppe Sapienza, et al.
Published: (2024-09-01)

P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
by: T. Thavayogarajah, et al.
Published: (2022-06-01)

Datenmanagement im SFB 1313
by: Martin Schneider, et al.
Published: (2020-04-01)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
by: Desiree Kunadt, et al.
Published: (2022-09-01)

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
by: Jurjen Versluis, et al.
Published: (2017-02-01)

Allogeneic stem cell transplantation and minimal residual disease in patients with AML in first complete remission
by: Jurjen Versluis, et al.
Published: (2018-06-01)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
by: Xing-yu Cao, et al.
Published: (2023-12-01)

P427: THE SINGLE CELL T CELL LANDSCAPE OF AML PATIENTS POST ALLOGENEIC STEM CELL TRANSPLANTATION
by: A. Mathioudaki, et al.
Published: (2022-06-01)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
by: Weijie Cao, et al.
Published: (2022-11-01)

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.
by: Watson, M, et al.
Published: (1999)

P1313: LOW DOSE RITUXIMAB FOR PRE-EMPTIVE TREATMENT OF EPSTEIN BARR VIRUS REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY
by: Chen Mei, et al.
Published: (2023-08-01)

Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases
by: Voß Martin, et al.
Published: (2010-09-01)

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation
by: Max Jan, et al.
Published: (2019-07-01)

PB1768: MICRORNA SIGNATURES IMPLY A ROLE FOR FOXO IN AML CHEMO-RESISTANCE
by: Paula Reichelt, et al.
Published: (2023-08-01)

Maintenance therapy for AML after allogeneic HCT
by: Rahul K. Nayak, et al.
Published: (2022-08-01)

P1337: SURVIVAL EFFICACY OF MDS/AML PATIENTS WITH TP53 GENE ALTERATION RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: D. Feng, et al.
Published: (2022-06-01)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
by: Goodyear, O, et al.
Published: (2012)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
by: Jan Braune, et al.
Published: (2022-01-01)

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
by: Michael Medinger, et al.
Published: (2023-08-01)

Photoinduced Dynamics of 13,13′-Diphenylpropyl-β-carotene
by: Sangho Koo, et al.
Published: (2023-04-01)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
by: Inna Shaforostova, et al.
Published: (2023-08-01)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
by: S. Chen, et al.
Published: (2022-06-01)

Granulocytic Sarcoma by AML M4eo (inv16) after Allogeneic Stem Cell Transplantation without Bone Marrow Involvement
by: Stephan Zaenker, et al.
Published: (2011-01-01)

The Evolution of the Meaning of the Word “Hamasah” until 1313 (Millennium of Ferdowsi)
by: Fatemeh Hemmasiyan Kashan, et al.
Published: (2023-02-01)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
by: Mona Hassanein, et al.
Published: (2021-05-01)

Characterization of factors determining the kinetics of disease relapse after allogeneic Stem Cell Transplantation (allo-SCT) or chemotherapeutic consolidation for Acute Myeloid Leukaemia (AML) in First CR: A survey from HOVON-SAKK and the acute leukaemia working party of the EBMT
by: Craddock, C, et al.
Published: (2016)

Prenatal Diagnosis of Translocation 13;13 Patau Syndrome: Clinical Features of Two Cases
by: Pazarbaşi A, et al.
Published: (2008-01-01)